
Current Price | $0.63 | Mkt Cap | $119.6M |
---|---|---|---|
Open | $0.64 | P/E Ratio | -0.29 |
Prev. Close | $0.63 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.62 - $0.65 | Volume | 1,653,740 |
52-Wk Range | $0.60 - $5.18 | Avg. Daily Vol. | 4,913,561 |
A biopharmaceutical company which develops breakthrough products that make a difference in patients' lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.
Current Price | $0.63 | Mkt Cap | $119.6M |
---|---|---|---|
Open | $0.64 | P/E Ratio | -0.29 |
Prev. Close | $0.63 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.62 - $0.65 | Volume | 1,653,740 |
52-Wk Range | $0.60 - $5.18 | Avg. Daily Vol. | 4,913,561 |
The best Bull and Bear pitches based on recency and number of recommendations.
Punished too much for manufacturing issues.
many alternatives to opiods for pain which doesn't include 181. results for stand alone opdivo, keytruda for cancer melanoma, RCC are already robust. minimal benefit for 214 combo, or even arguably, no CLEAR benefit with the addition of 214. also,… More
Read the most recent pitches from players about NKTR.
Recs
Punished too much for manufacturing issues.
Recs
Reasonable pipeline despite near term uncertainty.
Recs
NKTR took off on its oncology platform but also has an interesting opioid agonist for pain that is fast tracked because of its potential to be less addictive. this could be huge if approved.
Find the members with the highest scoring picks in NKTR.
anticitradeshort (27.22) Score: +484.98
The Score Leader is the player with the highest score across all their picks in NKTR.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
anticitradeshort | 27.22 | 4/20/2009 |
![]() |
NS | $5.64 | -88.61% | +396.37% | +484.98 | 0 Comment | |
lanceur | 62.05 | 5/21/2009 |
![]() |
5Y | $6.62 | -90.30% | +374.62% | +464.91 | 0 Comment | |
anticitrademix2 | < 20 | 11/2/2009 |
![]() |
5Y | $8.15 | -92.12% | +303.55% | +395.67 | 0 Comment | |
anticitrademix | < 20 | 11/2/2009 |
![]() |
5Y | $8.15 | -92.12% | +303.55% | +395.67 | 0 Comment | |
shorttest4 | 31.06 | 3/8/2010 |
![]() |
5Y | $15.07 | -95.74% | +267.77% | +363.51 | 0 Comment | |
Finonzo | < 20 | 8/11/2011 |
![]() |
5Y | $5.15 | -87.53% | +269.88% | +357.40 | 0 Comment | |
anticishort | 32.14 | 3/30/2010 |
![]() |
5Y | $15.39 | -95.83% | +257.75% | +353.58 | 0 Comment | |
Bill292 | 27.80 | 12/16/2011 |
![]() |
5Y | $5.23 | -87.72% | +245.60% | +333.32 | 0 Comment | |
Experiment200806 | < 20 | 6/30/2008 |
![]() |
NS | $3.45 | -81.38% | +238.93% | +320.31 | 0 Comment | |
drakitin | 99.04 | 8/15/2008 |
![]() |
1Y | $5.11 | -87.43% | +232.62% | +320.05 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.